HMG-CoA reductase inhibitors and renal function.
Campese
Vito M
VM
Park
Jeanie
J
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000069059:Atorvastatin; D002908:Chronic Disease; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D007674:Kidney Diseases / Q000503:physiopathology; D008077:Lipoproteins, LDL / Q000633:toxicity; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D011758:Pyrroles; D000069059:Atorvastatin